tiprankstipranks
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
US Market
OLMA
Olema Pharmaceuticals
RESEARCH TOOLSreports
Want to see OLMA full AI Analyst Report?

Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

1,013 Followers
See the Price Targets and Ratings of:

OLMA Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Olema
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OLMA Stock 12 Month Forecast

Average Price Target

$37.50
▲(243.72% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $37.50 with a high forecast of $59.00 and a low forecast of $20.00. The average price target represents a 243.72% change from the last price of $10.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","18":"$18","32":"$32","46":"$46","60":"$60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$59.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18,32,46,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.45,15.107692307692307,18.765384615384615,22.42307692307692,26.080769230769228,29.738461538461536,33.396153846153844,37.05384615384615,40.71153846153846,44.36923076923077,48.02692307692307,51.684615384615384,55.342307692307685,{"y":59,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.45,13.453846153846154,15.457692307692307,17.46153846153846,19.465384615384615,21.46923076923077,23.473076923076924,25.476923076923075,27.48076923076923,29.484615384615385,31.48846153846154,33.49230769230769,35.496153846153845,{"y":37.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.45,12.107692307692307,12.765384615384615,13.423076923076923,14.080769230769231,14.73846153846154,15.396153846153846,16.053846153846152,16.71153846153846,17.369230769230768,18.026923076923076,18.684615384615384,19.342307692307692,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.45,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$59.00Average Price Target$37.50Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on OLMA
Kelsey Goodwin
Piper Sandler
Piper Sandler
$40
Buy
266.64%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (NYSE: SNN) and Olema Pharmaceuticals (NASDAQ: OLMA)
J.P. Morgan Analyst forecast on OLMA
Anupam Rama
J.P. Morgan
J.P. Morgan
$46
Buy
321.63%
Upside
Reiterated
08/17/26
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
LifeSci Capital Analyst forecast on OLMA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$24
Buy
119.98%
Upside
Reiterated
08/11/26
Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained
H.C. Wainwright Analyst forecast on OLMA
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$36
Buy
229.97%
Upside
Reiterated
08/11/26
Olema Oncology price target lowered to $36 from $38 at H.C. WainwrightOlema Oncology price target lowered to $36 from $38 at H.C. Wainwright
Goldman Sachs Analyst forecast on OLMA
Richard Law CFA
Goldman Sachs
Goldman Sachs
$23→$20
Buy
83.32%
Upside
Reiterated
08/11/26
Olema Pharmaceuticals (OLMA) Receives a Buy from Goldman Sachs
TD Cowen Analyst forecast on OLMA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/10/26
Tyler Van Buren Reiterates Buy on Olema, Citing Palazestrant’s Late-Stage Differentiation and Multiple Value-Creating Catalysts
Citi Analyst forecast on OLMA
Yigal Nochomovitz
Citi
Citi
$62→$59
Buy
440.79%
Upside
Assigned
08/10/26
Olema Oncology price target lowered to $59 from $62 at CitiOlema Oncology price target lowered to $59 from $62 at Citi
UBS Analyst forecast on OLMA
Michael Yee
UBS
UBS
$45
Buy
312.47%
Upside
Reiterated
06/02/26
UBS Remains a Buy on Olema Pharmaceuticals (OLMA)
Guggenheim Analyst forecast on OLMA
Bradley Canino
Guggenheim
Guggenheim
$38→$35
Buy
220.81%
Upside
Reiterated
06/01/26
Olema Pharmaceuticals (OLMA) Gets a Buy from Guggenheim
Wolfe Research Analyst forecast on OLMA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
03/26/26
Olema Oncology initiated with a Peer Perform at Wolfe ResearchOlema Oncology initiated with a Peer Perform at Wolfe Research
Jefferies Analyst forecast on OLMA
Dennis Ding
Jefferies
Jefferies
$43→$40
Buy
266.64%
Upside
Initiated
03/19/26
Olema Oncology assumed with a Buy at JefferiesOlema Oncology assumed with a Buy at Jefferies
Stifel Nicolaus Analyst forecast on OLMA
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$48
Buy
339.96%
Upside
Initiated
02/11/26
Olema Oncology initiated with a Buy at StifelOlema Oncology initiated with a Buy at Stifel
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on OLMA
Kelsey Goodwin
Piper Sandler
Piper Sandler
$40
Buy
266.64%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (NYSE: SNN) and Olema Pharmaceuticals (NASDAQ: OLMA)
J.P. Morgan Analyst forecast on OLMA
Anupam Rama
J.P. Morgan
J.P. Morgan
$46
Buy
321.63%
Upside
Reiterated
08/17/26
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
LifeSci Capital Analyst forecast on OLMA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$24
Buy
119.98%
Upside
Reiterated
08/11/26
Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained
H.C. Wainwright Analyst forecast on OLMA
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$36
Buy
229.97%
Upside
Reiterated
08/11/26
Olema Oncology price target lowered to $36 from $38 at H.C. WainwrightOlema Oncology price target lowered to $36 from $38 at H.C. Wainwright
Goldman Sachs Analyst forecast on OLMA
Richard Law CFA
Goldman Sachs
Goldman Sachs
$23→$20
Buy
83.32%
Upside
Reiterated
08/11/26
Olema Pharmaceuticals (OLMA) Receives a Buy from Goldman Sachs
TD Cowen Analyst forecast on OLMA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/10/26
Tyler Van Buren Reiterates Buy on Olema, Citing Palazestrant’s Late-Stage Differentiation and Multiple Value-Creating Catalysts
Citi Analyst forecast on OLMA
Yigal Nochomovitz
Citi
Citi
$62→$59
Buy
440.79%
Upside
Assigned
08/10/26
Olema Oncology price target lowered to $59 from $62 at CitiOlema Oncology price target lowered to $59 from $62 at Citi
UBS Analyst forecast on OLMA
Michael Yee
UBS
UBS
$45
Buy
312.47%
Upside
Reiterated
06/02/26
UBS Remains a Buy on Olema Pharmaceuticals (OLMA)
Guggenheim Analyst forecast on OLMA
Bradley Canino
Guggenheim
Guggenheim
$38→$35
Buy
220.81%
Upside
Reiterated
06/01/26
Olema Pharmaceuticals (OLMA) Gets a Buy from Guggenheim
Wolfe Research Analyst forecast on OLMA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Initiated
03/26/26
Olema Oncology initiated with a Peer Perform at Wolfe ResearchOlema Oncology initiated with a Peer Perform at Wolfe Research
Jefferies Analyst forecast on OLMA
Dennis Ding
Jefferies
Jefferies
$43→$40
Buy
266.64%
Upside
Initiated
03/19/26
Olema Oncology assumed with a Buy at JefferiesOlema Oncology assumed with a Buy at Jefferies
Stifel Nicolaus Analyst forecast on OLMA
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$48
Buy
339.96%
Upside
Initiated
02/11/26
Olema Oncology initiated with a Buy at StifelOlema Oncology initiated with a Buy at Stifel
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Olema Pharmaceuticals

3 Months
Michael YeeUBS
Success Rate
11/19 ratings generated profit
58%
Average Return
+5.96%
Copying Michael Yee's trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +5.96% per trade.
1 Year
Emily BodnarH.C. Wainwright
Success Rate
15/28 ratings generated profit
54%
Average Return
+66.56%
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 53.57% of your transactions generating a profit, with an average return of +66.56% per trade.
2 Years
Emily BodnarH.C. Wainwright
Success Rate
16/28 ratings generated profit
57%
Average Return
+32.32%
Copying Emily Bodnar's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +32.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OLMA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
15
22
16
17
15
Buy
2
3
3
3
3
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
26
20
21
19
In the current month, OLMA has received 18 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. OLMA average Analyst price target in the past 3 months is 37.50.
Each month's total comprises the sum of three months' worth of ratings.

OLMA Financial Forecast

OLMA Earnings Forecast

Next quarter’s earnings estimate for OLMA is -$0.64 with a range of -$0.73 to -$0.50. The previous quarter’s EPS was -$0.61. OLMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.
Next quarter’s earnings estimate for OLMA is -$0.64 with a range of -$0.73 to -$0.50. The previous quarter’s EPS was -$0.61. OLMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.
No data currently available

OLMA Sales Forecast

Next quarter’s sales forecast for OLMA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. OLMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.
Next quarter’s sales forecast for OLMA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. OLMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.

OLMA Stock Forecast FAQ

What is OLMA’s average 12-month price target, according to analysts?
Based on analyst ratings, Olema Pharmaceuticals’s 12-month average price target is 37.50.
    What is OLMA’s upside potential, based on the analysts’ average price target?
    Olema Pharmaceuticals has 243.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OLMA a Buy, Sell or Hold?
          Olema Pharmaceuticals has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Olema Pharmaceuticals’s price target?
            The average price target for Olema Pharmaceuticals is 37.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $59.00 ,the lowest forecast is $20.00. The average price target represents 243.72% Increase from the current price of $10.91.
              What do analysts say about Olema Pharmaceuticals?
              Olema Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of OLMA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.